A biotechnology company, INOVIO, says the first participant in Lassa vaccine trial has been dosed – Viral9ja Verified Song Verified News Verified Gist Download Now WaW

A biotechnology company, INOVIO, says the first participant in Lassa vaccine trial has been dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever.

The clinical trial is being done in Ghana, the firm says, adding that INOVIO is focused on bringing to market precisely-designed DNA medicines to treat and protect people from infectious diseases and cancer.

The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa Fever to be conducted in West Africa, where the infection is endemic.

The lead clinical Principal Investigator for LSV-002 is Professor Dr. Kwadwo A. Koram, an expert and specialist in tropical medicines and epidemiologist with more than 20 years of research experience, including malaria vaccines.

INO-4500 was also the first vaccine candidate for Lassa fever to enter human trials, PUNCH Healthwise reports.

Already, the Director-General of the Nigeria Centre for Disease Control, Dr. Chikwe Ihekweazu, has tweeted his commendation.

Said Ihekweazu, “Fantastic news. The urgency of now. A vaccine for Lassa fever. We have worked very hard with WHO, CEPI vaccines, ACEGID, BNITM_de and many others to put this on the global health agenda. We will keep pushing.”

About the author

viral9ja

Writer !Artist Manager! Singer ! Accountant! PROMOTER

Leave a Comment

Open chat